Browse PIGU

Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF06728 GPI transamidase subunit PIG-U
Function

Component of the GPI transamidase complex. May be involved in the recognition of either the GPI attachment signal or the lipid portion of GPI.

> Gene Ontology
 
Biological Process GO:0006497 protein lipidation
GO:0006505 GPI anchor metabolic process
GO:0006506 GPI anchor biosynthetic process
GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006664 glycolipid metabolic process
GO:0007259 JAK-STAT cascade
GO:0008654 phospholipid biosynthetic process
GO:0009247 glycolipid biosynthetic process
GO:0016255 attachment of GPI anchor to protein
GO:0042157 lipoprotein metabolic process
GO:0042158 lipoprotein biosynthetic process
GO:0045017 glycerolipid biosynthetic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046467 membrane lipid biosynthetic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0097696 STAT cascade
GO:1903509 liposaccharide metabolic process
GO:1904892 regulation of STAT cascade
Molecular Function GO:0003923 GPI-anchor transamidase activity
GO:0005543 phospholipid binding
GO:0034235 GPI anchor binding
GO:0035091 phosphatidylinositol binding
GO:0051861 glycolipid binding
Cellular Component GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0042765 GPI-anchor transamidase complex
> KEGG and Reactome Pathway
 
KEGG hsa00563 Glycosylphosphatidylinositol(GPI)-anchor biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-162791: Attachment of GPI anchor to uPAR
R-HSA-392499: Metabolism of proteins
R-HSA-163125: Post-translational modification
R-HSA-597592: Post-translational protein modification
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PIGU and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PIGU in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.37; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.78; FDR: 0.00545 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PIGU in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2060.382
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1410.947
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.260.876
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0320.893
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1060.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0670.966
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1390.664
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3560.786
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1080.94
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0380.978
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0980.964
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.170.043
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PIGU in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIGU. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIGU. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIGU.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIGU. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PIGU expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PIGU and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPIGU
Namephosphatidylinositol glycan anchor biosynthesis, class U
Aliases bA346K17.2; CDC91L1; CDC91 (cell division cycle 91, S. cerevisiae, homolog)-like 1; CDC91 cell division cycl ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PIGU collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.